DNAmic

(Biotechnology, Medicine and Health)

Introduction

DNAmic Biosystems is a biopharmaceutical company in the preclinical phase with presence in California and Valencia, dedicated to developing pioneering technologies in programmable and guided cell engineering within the own body. Our approach goes beyond current therapies: we seek to completely transform the way diseases are treated, opening up a new field in medicine where the body’s own cells can be precisely reprogrammed to restore health.

A New Paradigm in Cell Therapy

Gene and cell therapies have revolutionized the treatment of multiple diseases, but they still face a fundamental limitation: the inability to reprogram cells within the body in a safe, efficient and controlled way. DNAmic has developed a modular cellular bioengineering platform capable of restoring and modifying cell function without the need to modify DNA or rely on invasive procedures or ex vivo therapies.

Our technology is based on fully human programmable nanoparticles, designed to transport therapeutic molecules in a targeted way to specific cells. This allows them to be reprogrammed in vivo, either to reverse diseases or to endow them with new therapeutic functions. The idea is to have the potential to reprogram any cell, tissue or organ in the body, which could mean the ability to cure virtually any disease.

A New Era in Medicine

Traditional medicine is based on treating symptoms or replacing damaged cells. At DNAmic, we believe in a different approach: directly modifying the cells within the body so that they function properly again. This approach could not only eliminate the need for many surgeries, transplants or invasive therapies, but it would also allow fully customized treatments based on the patient’s biology to be developed.

Innovation, security and strategic collaboration

DNAmic Biosystems was co-founded by the entrepreneur Alfonso Fiz and Dr. Jesús Beltrán, combining extensive experience in bioengineering, cellular reprogramming and business development to bring this vision into reality. Our business model is based on collaboration with international laboratories, research centers and pharmaceutical companies, establishing co-development, licensing and marketing agreements.

Guided and biocompatible cell engineering is not just a new medical tool, it’s a revolution in the way we understand and treat disease. At DNAmic we are building that revolution, where the cells of the body can be precisely reprogrammed and guided to cure diseases from their roots.

 

Technology offer

Technical Specifications

DNAmic Biosystems' technology is based on a human-derived programmable nanoparticles platform, designed to reprogram cells precisely within the body. Its modular architecture allows for targeted, safe and highly efficient therapeutic administration.

The system consists of three key components:

Core (structural core and therapeutic cargo vehicle):

  • Composed of an engineered human protein, optimized to identify, encapsulate and protect therapeutic molecules.
  • Able to transport RNA, DNA, proteins and combinations of different molecules simultaneously.
  • It has a loading capacity of more than 12,000 bases, far exceeding current therapeutic delivery technologies.

Cargo (transported therapeutic molecules):

  • The platform enables multiple types of therapies to be delivered in a single system, including RNA for cell reprogramming, therapeutic proteins and gene editing systems such as CRISPR-Cas.
  • Potential to treat various diseases, from cancer and immunotherapy to neurodegenerative and metabolic diseases.
  • The charge is flanked by our regulatory gene circuits, allowing perfect cargo encapsulation and efficient reading and use by the target cell.

Envelope (cellular addressing and fusion system):

  • Based on a redesigned human protein with the ability to fuse with cell membranes.
  • Optimized to eliminate its natural interaction with cells of the body and reprogrammed to target selectively specific cells.
  • It has an affinity equal to or even greater than that of an antibody for its receptor, allowing unprecedented precision in therapeutic delivery.

Innovation and intellectual property

This breakthrough has resulted in two key patents, one for the Core and one for the Envelope.

Benefits of Technology

Innovative aspects and competitive advantages

1. Human Protein-based Modular Cell Engineering Platform

DNAmic Biosystems has developed a modular cell bioengineering platform, designed from optimized human proteins. This innovative approach eliminates dependence on viral vectors or synthetic nanoparticles, significantly reducing the toxicity and immunogenicity problems that constrain conventional delivery systems. The ability to modulate its structure allows the platform to adapt to different therapeutic needs, providing a universal solution for cell reprogramming within the body.

2. In Vivo Cellular Reprogramming Directed

Unlike traditional cell therapies, which require the extraction, manipulation and reintroduction of cells into the body, DNAmic technology allows cell reprogramming directly within the body. This eliminates the need for invasive procedures and allows treatment to be more accessible, faster and safer for the patient. With this approach, cells can be modified to restore their function, eliminate pathologies or give them new therapeutic capabilities without permanently altering the DNA.

3. Superior Therapeutic Load Capacity

Another disruptive development of this platform is its therapeutic load capacity. DNAmic has designed a system that can encapsulate more than 12,000 RNA or DNA bases, far exceeding the capabilities of current delivery systems. This capability allows the administration of messenger RNA, gene editing systems, therapeutic proteins and even combinations of different molecules in a single formulation.

4. Specific Cell Address and Improved Affinity

The DNAmic platform incorporates a high-precision cellular addressing mechanism, based on human proteins optimized to interact exclusively with target cells. The envelope of nanoparticles has been redesigned to eliminate their non-target cell interaction and redirect them with an affinity equal to or even greater than that of an antibody for its specific receptor. This ensures that therapy is delivered only to the cells that require it, improving efficacy and dramatically reducing side effects associated with systemic drug administration.

5. Virus-free and Non-integrative Technology

The system developed by DNAmic does not use viral vectors or permanently alter the genome of cells. This non-integrative technology allows transient modification of cell function without the risk of mutagenesis, oncogenic activation or adverse immunological responses. By avoiding irreversible genetic manipulation, a more secure and flexible platform is achieved, with applications in precision therapies that can be dynamically adapted to the patient’s needs.

6. Versatile Therapeutic Applications

The potential of this technology extends to various therapeutic areas. In the field of immunotherapy, DNAmic has developed CAR-T therapies in vivo, allowing direct reprogramming of T lymphocytes within the patient to attack tumors more effectively. In addition, work is being done on guided cell engineering in macrophages, designing strategies to teach them how to detect and eliminate viruses before they even infect human cells. The first application of this approach is being tested on HIV, with the possibility of spreading to other viral infections. Beyond immunotherapy, this platform opens up new opportunities to treat neurodegenerative, autoimmune and metabolic diseases such as diabetes, offering solutions where current treatments have proven insufficient.

7. High Scalability and Ease of Production

One of the challenges in the development of advanced therapies is their large-scale feasibility. The DNAmic platform is designed with an industrial scalability approach, using reprogrammed human proteins, capable of being produced by existing manufacturing processes in the biopharmaceutical industry. This feature reduces production costs and accelerates the arrival of technology on the market, facilitating its adoption in clinical settings.

8. Safety and Side Effect Reduction

Based on human proteins, DNAmic has designed a platform with a superior security profile. In addition, the precision of cell targeting minimizes systemic toxicity, while the ability to temporarily modify cell function avoids the long-term risks associated with genetic manipulation.

9. Solid Intellectual Property

DNAmic has protected its technology through two key patents, one for the Core-Cargo and one for the Envelope, consolidating its position in the field of guided cell engineering. This intellectual property supports the platform’s commercial viability and strengthens opportunities for partnerships with academic institutions, laboratories and the pharmaceutical industry.

10. Business Model Based on Strategic Collaborations

DNAmic’s business model is based on collaboration with research laboratories, academic centers and biopharmaceutical companies, establishing co-development, licensing and marketing agreements. These partnerships accelerate the preclinical and clinical validation of technology, facilitating its access to patients and maximizing its impact on precision medicine.

Building the Future of Medicine

Our guided cell engineering platform has the potential to reprogram any cell in the body with unprecedented precision, offering a completely innovative approach to treating disease from its root. This development represents a transformation in the way we understand and apply biotechnology in the clinical field, opening up new possibilities for treating complex diseases that had no effective solution until now.

Technology Applications

DNAmic is currently actively developing therapies in four key areas:

Oncology

We are developing CAR-T therapies in vivo, eliminating the need to modify cells outside the body. This strategy allows for direct reprogramming of the patient’s T lymphocytes to attack tumors with greater efficiency and less toxicity. We are currently exploring applications in refractory B-cell leukemia and non-Hodgkin lymphoma.

Autoimmune and metabolic diseases

Our technology enables precision immunological modulation, reprogramming B, T and myeloid cells to restore immune balance without generalized immunosuppression. Early applications include type 1 diabetes, rheumatoid arthritis and multiple sclerosis, where we seek to slow the progression of the disease while preserving immune function.

Infectious diseases

We are developing cell engineering in macrophages to teach them how to detect and eliminate viruses and bacteria in incurable infectious diseases. Our first model focuses on HIV, with the aim of eradicating both the virus itself and viral reservoirs, allowing a functional cure. We are also researching strategies to combat multi-resistant bacteria, offering an alternative to conventional antibiotics and new infections.

Ageing and regeneration

Our platform allows cell reprogramming to restore functions lost with age. Early applications include sarcopenia, promoting muscle regeneration, and neuroprotection in cognitive impairment and neurodegenerative diseases, with an initial focus on Alzheimer’s.

Sectors to which company is directed
  • Health Sector
  • Pharmaceutical and biotechnology industry

Team

Alfonso Fiz

Co-founder and executive director

Jesus Beltran

PhD - Co-founder and Scientific Director

José Aparicio

PhD - Director of Preclinical Research

Pedro Fernández

Legal director

DNAmic company news

The company specialized in cellular bioengineering DNAmic is incorporated into the UV Science ParkRead more »

Contact information

Alfonso Fiz MuñozCEOalfonso.fiz@dnamic.bioMobile Phone: 670572356